Pharvaris (PHVS) Equity Average (2022)

Pharvaris (PHVS) reported Equity Average of $76.2 million for Q4 2022.

Pharvaris (PHVS) Equity Average (2022) Analysis & Trends

Pharvaris has reported Equity Average for 1 years, with the latest figure at $76.2 million in Q4 2022.

For the quarter ending Q4 2022, Equity Average changed N/A year-over-year to $76.2 million; the trailing twelve-month figure through Dec 2022 stood at $76.2 million (changed N/A YoY), and the FY2025 full-year result was $298.1 million, down 15.45% from the prior year.
Equity Average for Q4 2022 stood at $76.2 million.
The five-year high for Equity Average was $76.2 million in Q4 2022, with the low at $76.2 million in Q4 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Avg. (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	3.50 Bn
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	783.14 Mn
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	3.76 Mn
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	1.01 Bn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	21.35 Mn
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	19.01 Bn
9	Abivax	90.15 Bn	90.15 Bn	-	516.41 Mn
10	Pharvaris	28.66 Bn	28.37 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2022	76.24 Mn